NCT00889044 is a Phase 3 clinical trial of clopidogrel by chewing in Platlet Aggregation, sponsored by Sheba Medical Center.

Who is sponsoring NCT00889044?

NCT00889044 is sponsored by Sheba Medical Center.

What drugs are being tested in NCT00889044?

Interventions in NCT00889044: clopidogrel by chewing, Placebo.

What condition does NCT00889044 study?

NCT00889044 studies Platlet Aggregation, Major Bleeding Outcomes.

Is NCT00889044 still recruiting?

NCT00889044 is currently status unknown. Last updated 26 April 2009.

Last reviewed 2009-04-26 · How we verify

NCT00889044

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI

Status unknown Phase 3 Last updated 26 April 2009

What this trial tests

Phase 3 trial testing clopidogrel by chewing in Platlet Aggregation in 30 participants. Status unknown.

Timeline

1 April 2009

Primary endpoint
1 December 2010

1 June 2011

Quick facts

Lead sponsor	Sheba Medical Center
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	quadruple
Primary purpose	treatment
Enrollment	30
Start date	1 April 2009
Primary completion	1 December 2010
Estimated completion	1 June 2011
Sites	2 locations across Israel

Drugs / interventions tested

clopidogrel by chewing — full drug profile →
Placebo

Conditions studied

Platlet Aggregation — all drugs for Platlet Aggregation →
Major Bleeding Outcomes — all drugs for Major Bleeding Outcomes →

Sponsor

Sheba Medical Center

Who can join

18 and older, any sex, with Platlet Aggregation or Major Bleeding Outcomes. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Platelet aggregation and bleeding events
Time frame: 6 months

Sponsor's own description

Since the absorption of clopidogrel through the gastrointestinal tract is limited, we want to examine whether adding clopidogrel by chewing will overcome the limited gastrointestinal absorption, and hence will improve the prevention of platelet aggregation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sheba Medical Center trials

Trials by the same sponsor.

NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
NCT07523373 — Facial Nerve Monitoring During Parotid and Facial Surgery Using a Non-Invasive Patch · NA · not yet recruiting
NCT07509229 — 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients · Phase 1, PHASE2 · not yet recruiting
NCT07405723 — Arm Position and Blood Pressure Measurement Accuracy During Pregnancy · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00889044 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sheba Medical Center
Last refreshed: 26 April 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00889044.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing